MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
58.13
+0.98
+1.71%
After Hours: 57.50 -0.63 -1.08% 19:34 02/06 EST
OPEN
57.26
PREV CLOSE
57.15
HIGH
58.43
LOW
57.26
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
73.51
52 WEEK LOW
50.76
MARKET CAP
11.17B
P/E (TTM)
21.79
1D
5D
1M
3M
1Y
5Y
1D
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum
Simply Wall St · 2h ago
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts
Benzinga · 16h ago
BioMarin Pharmaceutical Price Target Cut to $84.00/Share From $122.00 by Piper Sandler
Dow Jones · 19h ago
BioMarin Pharmaceutical Is Maintained at Overweight by Piper Sandler
Dow Jones · 19h ago
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $84
Benzinga · 19h ago
BIOMARIN PHARMACEUTICAL INC <BMRN.O>: PIPER SANDLER CUTS TARGET PRICE TO $84 FROM $122
Reuters · 1d ago
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Seeking Alpha · 3d ago
Weekly Report: what happened at BMRN last week (0126-0130)?
Weekly Report · 5d ago
More
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.